Boyd L. Harrison

Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer’s Disease

Robert Martone, Hua Zhou, Kevin Atchison et al. · Journal of Pharmacology and Experimental Therapeutics · 2009 · 157 citations

WAY-163909 [(7 bR,10 aR)-1,2,3,4,8,9,10,10 a-Octahydro-7 bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity

Karen L. Marquis, Annmarie L. Sabb, Sheree F. Logue et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 145 citations

NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations

John H. Kehne, Timothy C. McCloskey, Bruce M. Baron et al. · European Journal of Pharmacology · 1991 · 127 citations

Potential Anxiolytic Effects, Medicine, Mechanism Of Action +6

Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1 <i>H</i> -pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid) _A Receptor

Gabriel Martinez Botella, Francesco G. Salituro, Boyd L. Harrison et al. · Journal of Medicinal Chemistry · 2017 · 119 citations · Full text

Discovery of Begacestat, a Notch-1-Sparing γ-Secretase Inhibitor for the Treatment of Alzheimer’s Disease

Scott C. Mayer, Anthony F. Kreft, Boyd L. Harrison et al. · Journal of Medicinal Chemistry · 2008 · 109 citations · Full text

Stable Analogue 10, Alzheimer ’, Social Sciences +19